

CITATION REPORT

List of articles citing

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

DOI: 10.1002/14651858.cd008933.pub2
The Cochrane Library, 2013, , CD008933.

Source: <https://exaly.com/paper-pdf/55914633/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
98	Rituximab for relapsing-remitting multiple sclerosis. <i>The Cochrane Library</i> , 2013 , CD009130	5.2	25
97	Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. <i>Clinical Cancer Research</i> , 2013 , 19, 6863-72	12.9	25
96	Was nützt MS-Patienten am meisten?. <i>InFo Neurologie & Psychiatrie</i> , 2013 , 15, 8-8	0	
95	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 1339-49	3.1	13
94	Alemtuzumab in the treatment of multiple sclerosis. <i>Journal of Inflammation Research</i> , 2014 , 7, 19-27	4.8	7
93	CD84 is markedly up-regulated in Kawasaki disease arteriopathy. <i>Clinical and Experimental Immunology</i> , 2014 , 177, 203-11	6.2	8
92	Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis. <i>Immunology</i> , 2014 , 143, 219-29	7.8	22
91	Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together. <i>Journal of the Neurological Sciences</i> , 2014 , 347, 408-10	3.2	4
90	Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2014 , 3, 133	3	5
89	Daclizumab (anti-CD25) in multiple sclerosis. <i>Experimental Neurology</i> , 2014 , 262 Pt A, 44-51	5.7	33
88	Dimethyl fumarate for multiple sclerosis. 2014 ,		3
87	Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. <i>Clinical and Experimental Immunology</i> , 2014 , 175, 359-72	6.2	32
86	Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis. <i>Advances in Therapy</i> , 2014 , 31, 915-31	4.1	25
85	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>Cochrane Database of Systematic Reviews</i> , 2014 , CD009333		16
84	Alemtuzumab for multiple sclerosis. 2014 ,		1
83	Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions. <i>BMC Neurology</i> , 2014 , 14, 164	3.1	2
82	An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. <i>Brain and Behavior</i> , 2015 , 5, e00362	3.4	106

81	Co-ultramicrosized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells. <i>Scientific Reports</i> , 2015 , 5, 16676	4.9	26
80	Clinical trials in noninfectious uveitis. <i>International Ophthalmology Clinics</i> , 2015 , 55, 79-110	1.7	13
79	An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. <i>Patient Preference and Adherence</i> , 2015 , 9, 675-84	2.4	21
78	Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. <i>Drug, Healthcare and Patient Safety</i> , 2015 , 7, 157-67	1.6	19
77	The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0144538	3.7	26
76	Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?. <i>World Journal of Clinical Cases</i> , 2015 , 3, 545-55	1.6	115
75	Alzheimer's Disease: Exploring the Role of Inflammation and Implications for Treatment. <i>International Journal of Alzheimer's Disease</i> , 2015 , 2015, 515248	3.7	30
74	Managing Neuropsychological Impairment in Multiple Sclerosis: Pilot Study on a Standardized Metacognitive Intervention. <i>International Journal of MS Care</i> , 2015 , 17, 130-7	2.3	21
73	An assessment of genetic counseling services for individuals with multiple sclerosis. <i>Journal of Genetic Counseling</i> , 2015 , 24, 46-57	2.5	2
72	A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol. <i>BMC Neurology</i> , 2015 , 15, 128	3.1	9
71	The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. <i>Annals of Internal Medicine</i> , 2015 , 162, 777-84	8	2670
70	Comparative efficacy and acceptability of psychotherapies for acute anxiety disorders in children and adolescents: study protocol for a network meta-analysis. <i>BMJ Open</i> , 2015 , 5, e008572	3	9
69	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1159-71	5	30
68	Current role of chemotherapy and bone marrow transplantation in multiple sclerosis. <i>Current Treatment Options in Neurology</i> , 2015 , 17, 324	4.4	3
67	The Production Processes and Biological Effects of Intravenous Immunoglobulin. <i>Biomolecules</i> , 2016 , 6, 15	5.9	44
66	Psychological interventions for enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis. <i>The Cochrane Library</i> , 2016 ,	5.2	
65	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>The Cochrane Library</i> , 2016 , 11, CD009333	5.2	25
64	Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices. <i>Current Neurology and Neuroscience Reports</i> , 2016 , 16, 68	6.6	12

63	Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis - A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 8, 93-5	4	2
62	Human Adipose Stromal/Stem Cells from Obese Donors Show Reduced Efficacy in Halting Disease Progression in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. <i>Stem Cells</i> , 2016 , 34, 614-26	5.8	48
61	Alemtuzumab for multiple sclerosis. <i>The Cochrane Library</i> , 2016 , 4, CD011203	5.2	15
60	Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study. <i>Experimental Biology and Medicine</i> , 2016 , 241, 620-357	3.7	47
59	Disease-modifying therapies and infectious risks in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2016 , 12, 217-33	15	148
58	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1287-1295	6.5	63
57	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 520-32	5	30
56	Treatment decisions in multiple sclerosis - insights from real-world observational studies. <i>Nature Reviews Neurology</i> , 2017 , 13, 105-118	15	126
55	Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. <i>Neurology</i> , 2017 , 88, 677-684	6.5	15
54	Adrenocorticotrophic hormone methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2017 , 10, 3-17	6.6	14
53	Evaluating the safety of β interferons in MS: A series of nested case-control studies. <i>Neurology</i> , 2017 , 88, 2310-2320	6.5	29
52	Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β 1a: an observational study SKORE. <i>Therapeutic Advances in Neurological Disorders</i> , 2017 , 10, 18-32	6.6	6
51	Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. <i>BMJ Open</i> , 2017 , 7, e018612	3	3
50	The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 1143-1153	5.1	14
49	Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017 , 3, 2055217317725102	10.2	27
48	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. <i>Neuroepidemiology</i> , 2017 , 48, 124-130	5.4	4
47	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 588-596	5	25
46	Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology. <i>Arquivos De Neuro-Psiquiatria</i> , 2017 , 75, 57-65	1.6	5

45	The Effects of Aerobic Exercise on the Recovery of Walking Ability and Neuroplasticity in People with Multiple Sclerosis: A Systematic Review of Animal and Clinical Studies. <i>Multiple Sclerosis International</i> , 2017 , 2017, 4815958	1.1	12
44	Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis. <i>Journal of Neurology</i> , 2018 , 265, 999-1009	5.5	16
43	Producing an evidence-based treatment information website in partnership with people affected by multiple sclerosis. <i>Health Science Reports</i> , 2018 , 1, e24	2.2	5
42	Co-Ultramicronized Palmitoylethanolamide/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells. <i>Molecular Neurobiology</i> , 2018 , 55, 103-114	6.2	14
41	Oligodendrocyte Progenitor Cell Cultures: A Model to Screen Neurotrophic Compounds for Myelin Repair. <i>Methods in Molecular Biology</i> , 2018 , 1727, 155-166	1.4	2
40	Palliative care interventions for people with multiple sclerosis. <i>The Cochrane Library</i> , 2018 ,	5.2	78
39	Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages. <i>BMC Neurology</i> , 2018 , 18, 162	3.1	15
38	A systematic survey shows that reporting and handling of missing outcome data in networks of interventions is poor. <i>BMC Medical Research Methodology</i> , 2018 , 18, 115	4.7	6
37	[MRI alterations in immunomodulation]. <i>Der Nervenarzt</i> , 2018 , 89, 945-957	0.5	4
36	Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318783767 ²		5
35	Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 25, 276-281	4	6
34	Historical and Current Concepts Regarding Urodynamics in Multiple Sclerosis Patients. <i>Current Bladder Dysfunction Reports</i> , 2019 , 14, 168-173	0.4	1
33	Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1371-1378	2.5	10
32	A Pilot Study Identifying Brain-Targeting Adaptive Immunity in Pediatric Extracorporeal Membrane Oxygenation Patients With Acquired Brain Injury. <i>Critical Care Medicine</i> , 2019 , 47, e206-e213	1.4	9
31	The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses. <i>Frontiers in Neurology</i> , 2018 , 9, 1150	4.1	22
30	The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101863	4	12
29	Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis. <i>The Cochrane Library</i> , 2020 , 7, CD013325	5.2	3
28	Siponimod for multiple sclerosis. <i>The Cochrane Library</i> , 2020 ,	5.2	1

27	Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis. <i>Annals of Neurology</i> , 2020 , 88, 123-136	9.4	10
26	Cyclophosphamide treatment in active multiple sclerosis. <i>Neurological Sciences</i> , 2021 , 42, 3775-3780	3.5	3
25	Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS. <i>Frontiers in Neurology</i> , 2020 , 11, 593527	4.1	2
24	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021 , 18, 905-919	6.4	6
23	Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD. <i>BMC Neurology</i> , 2021 , 21, 183	3.1	8
22	Outcome measures assisting treatment optimization in multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 1	5.5	0
21	Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. <i>PLoS ONE</i> , 2014 , 9, e113371	3.7	26
20	A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2015 , 10, e0127960	3.7	37
19	Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells. <i>PLoS ONE</i> , 2015 , 10, e0129182	3.7	18
18	Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. <i>Health Technology Assessment</i> , 2016 , 20, 1-48	4.4	14
17	Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017 , 21, 1-352	4.4	21
16	Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis. <i>Noropsikiyatri Arsivi</i> , 2017 , 54, 116-124	0.4	1
15	Mittel zur Behandlung der multiplen Sklerose. 2014 , 791-807		
14	Mittel zur Behandlung der multiplen Sklerose. 2015 , 799-820		
13	Preliminary Evidence-Based Pharmacotherapy of Mitoxantrone for Multiple Sclerosis in an Iranian Population. <i>Thrita</i> , 2015 , 4,	1.3	1
12	Mittel zur Behandlung der multiplen Sklerose. 2016 , 561-575		
11	Mittel zur Behandlung der multiplen Sklerose. 2017 , 571-587		
10	Mittel zur Behandlung der multiplen Sklerose. 2018 , 619-636		

9 Pharmakologische Behandlung der multiplen Sklerose. **2019**, 799-816

8 Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis. *BMJ Open*, **2021**, 11, e051509 3

7 How do immunomodulators and immunosuppressants compare for people with multiple sclerosis?. *Cochrane Clinical Answers*,

6 Siponimod for multiple sclerosis. *The Cochrane Library*, **2021**, 11, CD013647 5.2 2

5 Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders. *International Journal of Molecular Sciences*, **2021**, 22, 6.3 0

4 Assessment of fingolimod versus dimethyl fumarate for the treatment of multiple sclerosis; a 24-month follow-up study. *American Journal of Clinical and Experimental Immunology*, **2021**, 10, 86-92 1.2

3 Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.. *International Journal of Molecular Sciences*, **2022**, 23, 6.3 0

2 Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. **2022**, 2022, 0

1 Cathepsin-B inhibitor CA-074 attenuates retinopathy and optic neuritis in experimental autoimmune encephalomyelitis induced in SJL/J mice. **2022**, 0